TY - JOUR
T1 - Age at asthma diagnosis is related to prevalence and characteristics of asthma symptoms
AU - Hisinger-Mölkänen, Hanna
AU - Honkamäki, Jasmin
AU - Kankaanranta, Hannu
AU - Tuomisto, Leena
AU - Backman, Helena
AU - Andersen, Heidi
AU - Lindqvist, Ari
AU - Lehtimäki, Lauri
AU - Sovijärvi, Anssi
AU - Rönmark, Eva
AU - Pallasaho, Paula
AU - Ilmarinen, Pinja
AU - Piirilä, Päivi
N1 - Funding Information:
This research is supported by The Foundation of Ida Montin (Kerava, Finland), Allergy Reuter Foundation (Helsinki, Finland), The Foundation of Väinö and Laina Kivi (Helsinki, Finland), Tampere Tuberculosis Foundation (Tampere, Finland), The Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), The Research Foundation of the Pulmonary Diseases (Helsinki, Finland), Finnish Cultural Foundation (Pirkanmaa, Finland), The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland), The Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland), The Stockmann Foundation (Helsinki, Finland) and Nummela Sanatorium Foundation (Helsinki, Finland). None of the sponsors had any involvement in the planning, execution, drafting or write-up of this study.Päivi Piirilä reports financial support from NordForsk Foundation. Leena Tuomisto reports payments for lectures from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim. Helena Backman reports payments for scientific presentations from AstraZeneca and Boehringer Ingelheim. Hannu Kankaanranta reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi Pharma AB, GlaxoSmithKline, MSD, Orion Pharma, Novartis, Sanofi Genzyme and fees for lectures from AstraZeneca, Orion Pharma and Mundipharma. Lauri Lehtimäki reports payments for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK, Mundipharma, Novartis, Sanofi, Orion Pharma and additionally Advisory Boards participation for Alk, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, OrionPharma. LL reports owning stocks of Ausculthing Oy and being PI in clinical trials/studies sponsored by OrionPharma. Pinja Ilmarinen reports lecture fees from GlaxoSmithKline, Novartis, Mundipharma and AstraZeneca. Pinja Ilmarinen is an employee of GlaxoSmithKline. Hanna Hisinger-Mölkänen has been an employee of GlaxoSmithKline and is an employee of Orion Pharma. The other authors have no competing interests.
Funding Information:
Päivi Piirilä reports financial support from NordForsk Foundation. Leena Tuomisto reports payments for lectures from GlaxoSmithKline , AstraZeneca and Boehringer Ingelheim . Helena Backman reports payments for scientific presentations from AstraZeneca and Boehringer Ingelheim . Hannu Kankaanranta reports personal fees from AstraZeneca , Boehringer Ingelheim , Chiesi Pharma AB, GlaxoSmithKline , MSD , Orion Pharma, Novartis , Sanofi Genzyme and fees for lectures from AstraZeneca , Orion Pharma and Mundipharma . Lauri Lehtimäki reports payments for lectures from AstraZeneca , Boehringer Ingelheim , Chiesi , Circassia, GSK, Mundipharma , Novartis , Sanofi , Orion Pharma and additionally Advisory Boards participation for Alk, AstraZeneca , Boehringer Ingelheim , Chiesi , GSK, Novartis , Sanofi , OrionPharma. LL reports owning stocks of Ausculthing Oy and being PI in clinical trials/studies sponsored by OrionPharma. Pinja Ilmarinen reports lecture fees from GlaxoSmithKline , Novartis , Mundipharma and AstraZeneca . Pinja Ilmarinen is an employee of GlaxoSmithKline . Hanna Hisinger-Mölkänen has been an employee of GlaxoSmithKline and is an employee of Orion Pharma. The other authors have no competing interests.
Funding Information:
This research is supported by The Foundation of Ida Montin (Kerava, Finland), Allergy Reuter Foundation (Helsinki, Finland), The Foundation of Väinö and Laina Kivi (Helsinki, Finland), Tampere Tuberculosis Foundation (Tampere, Finland), The Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), The Research Foundation of the Pulmonary Diseases (Helsinki, Finland), Finnish Cultural Foundation (Pirkanmaa, Finland), The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland), The Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland), The Stockmann Foundation (Helsinki, Finland) and Nummela Sanatorium Foundation (Helsinki, Finland). None of the sponsors had any involvement in the planning, execution, drafting or write-up of this study.
Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Background: Although asthma may begin at any age, knowledge about relationship between asthma age of onset and the prevalence and character of different symptoms is scarce. Objectives: The aim of this study was to investigate if adult-diagnosed asthma is associated with more symptoms and different symptom profiles than child-diagnosed asthma. Methods: A FinEsS postal survey was conducted in a random sample of 16 000 20-69-year-old Finnish adults in 2016. Those reporting physician-diagnosed asthma and age at asthma diagnosis were included. Age 18 years was chosen to delineate child- and adult-diagnosed asthma. Results: Of responders (N = 8199, 51.5%), 842 (10.3%) reported asthma diagnosis. Adult-diagnosed asthma was reported by 499 (59.3%) and child-diagnosed by 343 (40.7%). Of responders with adult-diagnosed and child-diagnosed asthma, 81.8% versus 60.6% used asthma medication (p < 0.001), respectively. Current asthma was also more prevalent in adult-diagnosed asthma (89.2% versus 72.0%, p < 0.001). Risk factors of attacks of breathlessness during the last 12 months were adult-diagnosis (OR = 2.41, 95% CI 1.64–3.54, p < 0.001), female gender (OR = 1.49, 1.07–2.08, p = 0.018), family history of asthma (OR = 1.48, 1.07–2.04, p = 0.018) and allergic rhinitis (OR = 1.49, 1.07–2.09, p = 0.019). All the analysed asthma symptoms, except dyspnea in exercise, were more prevalent in adult-diagnosed asthma in age- and gender-adjusted analyses (p = 0.032-<0.001) which was also more often associated with 5 or more asthma symptoms (p < 0.001) and less often with non-symptomatic appearance (p < 0.001) than child-diagnosed asthma. Conclusion: Responders with adult-diagnosed asthma had more often current asthma and a higher and multiform asthma symptom burden, although they used asthma medication more often compared to responders with child-diagnosed asthma.
AB - Background: Although asthma may begin at any age, knowledge about relationship between asthma age of onset and the prevalence and character of different symptoms is scarce. Objectives: The aim of this study was to investigate if adult-diagnosed asthma is associated with more symptoms and different symptom profiles than child-diagnosed asthma. Methods: A FinEsS postal survey was conducted in a random sample of 16 000 20-69-year-old Finnish adults in 2016. Those reporting physician-diagnosed asthma and age at asthma diagnosis were included. Age 18 years was chosen to delineate child- and adult-diagnosed asthma. Results: Of responders (N = 8199, 51.5%), 842 (10.3%) reported asthma diagnosis. Adult-diagnosed asthma was reported by 499 (59.3%) and child-diagnosed by 343 (40.7%). Of responders with adult-diagnosed and child-diagnosed asthma, 81.8% versus 60.6% used asthma medication (p < 0.001), respectively. Current asthma was also more prevalent in adult-diagnosed asthma (89.2% versus 72.0%, p < 0.001). Risk factors of attacks of breathlessness during the last 12 months were adult-diagnosis (OR = 2.41, 95% CI 1.64–3.54, p < 0.001), female gender (OR = 1.49, 1.07–2.08, p = 0.018), family history of asthma (OR = 1.48, 1.07–2.04, p = 0.018) and allergic rhinitis (OR = 1.49, 1.07–2.09, p = 0.019). All the analysed asthma symptoms, except dyspnea in exercise, were more prevalent in adult-diagnosed asthma in age- and gender-adjusted analyses (p = 0.032-<0.001) which was also more often associated with 5 or more asthma symptoms (p < 0.001) and less often with non-symptomatic appearance (p < 0.001) than child-diagnosed asthma. Conclusion: Responders with adult-diagnosed asthma had more often current asthma and a higher and multiform asthma symptom burden, although they used asthma medication more often compared to responders with child-diagnosed asthma.
KW - Age of onset
KW - Asthma
KW - Late-onset
KW - Population study
KW - Symptom
U2 - 10.1016/j.waojou.2022.100675
DO - 10.1016/j.waojou.2022.100675
M3 - Article
AN - SCOPUS:85138063362
SN - 1939-4551
VL - 15
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
IS - 9
M1 - 100675
ER -